Rare Disease Commercialization: Beyond Approval
From The Emerging Biotech Leader by SSI Strategy
January 14, 2026 · 32 min · Episode 57
About this episode
The episode discusses the unique challenges of commercializing therapies for rare diseases with insights from Matt Trudeau of ITF Therapeutics.
In this episode of The Emerging Biotech Leader , host Kim Kushner sits down with Matt Trudeau, President of ITF Therapeutics , to discuss what it means to operate within a family-run pharmaceutical company and how that model shapes decision-making differently than a public or venture-backed organization. With more than 25 years of experience spanning Genzyme, Biogen, Bluebird Bio, and now ITF, Matt shares how his career has been defined by following the science, building commercial strategies, and putting rare disease patients at the center of every decision. He reflects on ITF’s journey in rare disease, exploring the unique challenges of commercializing therapies in underserved communities, from gaining regulatory approval to ensuring meaningful patient access and payer alignment. Matt also offers insights into: The evolving role of the patient voice post-approval and why commercialization is only the starting line. The balance of working across U.S. and European markets to deliver consistent value to small, global patient communities. Why the real challenge in rare diseases isn’t competing products, but overcoming complacency - ensuring patients gain access, education, and true…
People in this episode
Host: Kim Kushner
Guest: Matt Trudeau
Topics covered
- rare disease commercialization
- patient access
- pharmaceutical decision-making
- family-run companies
- regulatory approval
- global markets
- patient voice
Keywords
- rare disease
- commercialization
- patient access
- pharmaceutical industry
- regulatory approval
- global markets
- patient voice
- decision-making
- family-run companies
- healthcare
Mentioned in this episode
Organizations: ITF Therapeutics, Genzyme, Biogen, Bluebird Bio
More episodes of The Emerging Biotech Leader
- Designing Studies that Work in Complex Settings · May 22, 2026 · 19 min
- Rethinking Trial Design for Rare Diseases · May 8, 2026 · 37 min
- Driving Global Patient Access: Managed Access as a Strategic Lever · February 4, 2026 · 22 min
- Clinical Operations as a Strategic Function · December 2, 2025 · 21 min
- How Clinical Operations Shapes Biotech Strategy · November 20, 2025 · 46 min
- 50 Episodes in: Lessons from The Emerging Biotech Leader · November 10, 2025 · 36 min
Explore listener stats, chart rankings, contacts and more on the The Emerging Biotech Leader podcast page.